Be MOTIVATEd to participate!

MOTIVATE aims to capture different approaches to the management of patients with haemophilia A and inhibitors, including FVIII ITI with emicizumab. The study has huge potential to help us to understand the impact of treatment decisions.

Click here to read about our approach

Emicizumab is approved for bleed prevention in patients with and without inhibitors. However, emicizumab does not eradicate inhibitors. ITI remains the only clinically proven strategy to eradicate inhibitors and is still the recommended treatment approach.

Click here to learn more

Joint and bone damage in people with haemophilia A have major consequences throughout life. FVIII plays a role in preserving joint health and may be important for maintaining bone mass. We need to understand more about how our treatment decisions affect joint health, and find ways to detect early signs of joint and bone damage.

Click here to learn more

We need to understand more about how treatment decisions impact thrombotic risk in patients with inhibitors. MOTIVATE will monitor thrombotic risk during treatment with the different approaches.

Click here to find out how

MOTIVATE is a global effort to improve inhibitor patient care. Led by two coordinating investigators, Carmen Escuriola-Ettingshausen and Robert Sidonio Jr., and supported by a panel of experts, the study is bringing together valuable experience from around the world.

Click here to learn more